Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/FJC.0000000000001388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment.
Curr Cardiol Rep
June 2024
NYU Langone Health System, New York, NY, USA.
Purpose Of Review: Polyvascular disease has a significant global burden and is associated with increased risk of major adverse cardiac events with each additional vascular territory involved. The purpose of this review is to highlight the risk factors, associated outcomes, emerging genetic markers, and evidence for screening and treatment of polyvascular disease.
Recent Findings: Polyvascular disease is the presence of atherosclerosis in two or more vascular beds.
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Eur Heart J Acute Cardiovasc Care
December 2022
Professor of Pharmacology, Director Center of Epidemiology and Preventive Pharmacology, Director Laboratory of Lipoproteins, Immunity and Atherosclerosis Department of Pharmacological and Biomolecular Sciences Director Center for the Study of Atherosclerosis at Bassini Hospital University of Milan, Milan, Italy.
Article Synopsis
- Patients who have experienced acute coronary syndrome (ACS) are at high risk for recurrent cardiovascular events, particularly shortly after the initial event.
- The relationship between lowering low-density lipoprotein cholesterol (LDL-C) levels and reducing cardiovascular risks post-ACS has led to guidelines advocating for targeted lipid-lowering therapy (LLT), but many patients do not receive adequate treatment.
- A new approach suggests aggressively starting a combined treatment of high-intensity statins and ezetimibe immediately after ACS, along with mentioning innovative treatments like PCSK9 inhibitors, while also addressing barriers to effective patient care.
Step-wise Lipid-Lowering Therapy: Thinking Beyond the Guidelines.
J Cardiovasc Pharmacol
February 2023
Invasive Cardiology Unit, Pineta Grande Hospital, Castel Volturno, Italy.
What about chemoprevention for melanoma?
Curr Opin Oncol
March 2006
Skin Oncology Program, Department of Dermatology, Boston University School of Medicine, MA 02118, USA.
Purpose Of Review: This paper aims to critically review the potential for a chemoprevention strategy in melanoma, and to discuss new data on candidate chemoprevention agents, as chemoprevention has been suggested as an unexplored approach in melanoma.
Recent Findings: A strong scientific rationale, established long-term safety of candidate agents, and a systematic step-wise approach to chemoprevention agent development are all critical for melanoma chemoprevention research. Among potential agents, the lipid-lowering drugs, the statins, satisfy these prerequisites.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!